IL15 and neoplasm: In addition, AskGene Pharma designed ASKG915, a tumor-selective and cis-potentiated anti-PD-1 antibody-IL15 bispecific therapeutic, and ASKG915 was licensed to an IND in the first quarter of 2023 (103).